CN106661018B - 用作神经原纤维缠结显像剂的吡咯并[2,3-c]吡啶 - Google Patents
用作神经原纤维缠结显像剂的吡咯并[2,3-c]吡啶 Download PDFInfo
- Publication number
- CN106661018B CN106661018B CN201580031335.2A CN201580031335A CN106661018B CN 106661018 B CN106661018 B CN 106661018B CN 201580031335 A CN201580031335 A CN 201580031335A CN 106661018 B CN106661018 B CN 106661018B
- Authority
- CN
- China
- Prior art keywords
- mmol
- pyrrolo
- pyridin
- compound
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/079834 | 2014-06-13 | ||
| PCT/CN2014/079834 WO2015188368A1 (en) | 2014-06-13 | 2014-06-13 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| PCT/US2015/034794 WO2015191506A2 (en) | 2014-06-13 | 2015-06-09 | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106661018A CN106661018A (zh) | 2017-05-10 |
| CN106661018B true CN106661018B (zh) | 2019-07-19 |
Family
ID=54832744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580031335.2A Active CN106661018B (zh) | 2014-06-13 | 2015-06-09 | 用作神经原纤维缠结显像剂的吡咯并[2,3-c]吡啶 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9808542B2 (enExample) |
| EP (1) | EP3154970B1 (enExample) |
| JP (1) | JP6513107B2 (enExample) |
| KR (1) | KR102478430B1 (enExample) |
| CN (1) | CN106661018B (enExample) |
| AU (1) | AU2015274843B2 (enExample) |
| BR (1) | BR112016028345B1 (enExample) |
| CA (1) | CA2948528C (enExample) |
| DK (1) | DK3154970T3 (enExample) |
| ES (1) | ES2763095T3 (enExample) |
| HU (1) | HUE048395T2 (enExample) |
| MX (1) | MX375282B (enExample) |
| PL (1) | PL3154970T3 (enExample) |
| RU (1) | RU2695373C2 (enExample) |
| WO (2) | WO2015188368A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012397435B2 (en) | 2012-12-21 | 2017-03-30 | National Institutes For Quantum And Radiological Science And Technology | Novel compound for imaging TAU protein accumulated in the brain |
| SG11201811311VA (en) | 2016-07-22 | 2019-01-30 | Ac Immune Sa | Compounds for imaging tau protein aggregates |
| US10865207B2 (en) | 2016-07-22 | 2020-12-15 | Ac Immune S.A. | Compounds for imaging Tau protein aggregates |
| MX393052B (es) | 2017-06-02 | 2025-03-24 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar atrofia cerebral. |
| MX393700B (es) | 2017-06-02 | 2025-03-24 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar la ataxia espinocerebelosa. |
| WO2018221728A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | アルツハイマー型認知症予防または治療剤 |
| KR20220101001A (ko) * | 2017-06-02 | 2022-07-18 | 후지필름 도야마 케미컬 가부시키가이샤 | 타우병증 예방 또는 치료제 |
| US11666551B2 (en) | 2017-06-02 | 2023-06-06 | Fujifilm Toyama Chemical Co., Ltd. | Agent for reducing amount of amyloid β protein |
| EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| EP3743426A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| KR102017324B1 (ko) * | 2018-04-30 | 2019-09-02 | 경북대학교 산학협력단 | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 |
| CA3099318C (en) | 2018-05-09 | 2024-02-13 | Aprinoia Therapeutics Inc. | Heteroaryl compounds and uses thereof |
| WO2019236884A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN108676007B (zh) * | 2018-06-22 | 2020-06-26 | 厦门大学 | 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用 |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| EP4058065A4 (en) | 2019-11-13 | 2023-05-03 | Aprinoia Therapeutics Limited | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF |
| US20220008563A1 (en) * | 2020-07-10 | 2022-01-13 | The Regents Of The University Of California | Radiolabelled and nonradiolabelled pegylated compounds and uses thereof |
| JP2023536886A (ja) * | 2020-08-06 | 2023-08-30 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ハンチンチンタンパク質をイメージングするためのヘテロビアリール化合物及びイメージング剤 |
| CN112939753B (zh) * | 2020-09-15 | 2022-04-05 | 浙江大学 | 一种1-茚酮类化合物的合成方法 |
| KR102240400B1 (ko) * | 2020-11-19 | 2021-04-15 | 한국원자력연구원 | 베타-아밀로이드 검출용 수용성 화합물 |
| CN112745299B (zh) * | 2021-01-07 | 2022-01-25 | 温州大学 | 4-氰基-7,8-二氢异喹啉衍生物及其制备方法和应用 |
| TWI782769B (zh) * | 2021-10-28 | 2022-11-01 | 行政院原子能委員會核能研究所 | 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途 |
| CN114149425A (zh) * | 2021-11-16 | 2022-03-08 | 上海应用技术大学 | 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用 |
| CN114276259B (zh) * | 2022-01-04 | 2022-12-06 | 济川(上海)医学科技有限公司 | 一种马来酸二甲茚定关键中间体的制备方法 |
| CN115417816B (zh) * | 2022-09-05 | 2024-01-26 | 江苏南大光电材料股份有限公司 | 一种3,6-二溴-1-氯-异喹啉的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181075A1 (en) * | 2012-05-29 | 2013-12-05 | Merck Sharp & Dohme Corp. | Isotopically labeled biaryl urea compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451566A (en) * | 1993-11-17 | 1995-09-19 | Zeneca Limited | Herbicidal pyrrolopyridine compounds |
| CN101223166B (zh) * | 2004-10-07 | 2011-10-19 | 默沙东公司 | 噻唑基mglur5拮抗剂及其应用方法 |
| US20080027044A1 (en) * | 2006-06-13 | 2008-01-31 | Kim Lewis | Prodrug antibiotic screens |
| WO2008103615A1 (en) | 2007-02-21 | 2008-08-28 | Kalypsys, Inc. | Isoquinolines useful as inducible nitric oxide synthase inhibitors |
| TW200902499A (en) * | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| US20110076230A1 (en) | 2008-05-30 | 2011-03-31 | Barrow James C | Novel Substituted Indoles |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2012106343A2 (en) | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| US8684313B2 (en) | 2011-02-02 | 2014-04-01 | Ocean Rodeo Sports Inc. | Inflatable kite with leading edge swept forwards at wingtip |
| WO2013040183A1 (en) * | 2011-09-16 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof |
| CN103450152B (zh) * | 2012-06-04 | 2015-11-18 | 济南海乐医药技术开发有限公司 | 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物 |
| GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201404498D0 (en) * | 2014-03-13 | 2014-04-30 | Proximagen Ltd | New compounds |
-
2014
- 2014-06-13 WO PCT/CN2014/079834 patent/WO2015188368A1/en not_active Ceased
-
2015
- 2015-06-09 CA CA2948528A patent/CA2948528C/en active Active
- 2015-06-09 MX MX2016016384A patent/MX375282B/es active IP Right Grant
- 2015-06-09 US US15/317,333 patent/US9808542B2/en active Active
- 2015-06-09 JP JP2016572520A patent/JP6513107B2/ja active Active
- 2015-06-09 EP EP15806980.7A patent/EP3154970B1/en active Active
- 2015-06-09 RU RU2016150404A patent/RU2695373C2/ru active
- 2015-06-09 AU AU2015274843A patent/AU2015274843B2/en active Active
- 2015-06-09 HU HUE15806980A patent/HUE048395T2/hu unknown
- 2015-06-09 BR BR112016028345-7A patent/BR112016028345B1/pt active IP Right Grant
- 2015-06-09 DK DK15806980.7T patent/DK3154970T3/da active
- 2015-06-09 PL PL15806980T patent/PL3154970T3/pl unknown
- 2015-06-09 KR KR1020177000709A patent/KR102478430B1/ko active Active
- 2015-06-09 WO PCT/US2015/034794 patent/WO2015191506A2/en not_active Ceased
- 2015-06-09 ES ES15806980T patent/ES2763095T3/es active Active
- 2015-06-09 CN CN201580031335.2A patent/CN106661018B/zh active Active
-
2017
- 2017-10-04 US US15/724,402 patent/US10022461B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181075A1 (en) * | 2012-05-29 | 2013-12-05 | Merck Sharp & Dohme Corp. | Isotopically labeled biaryl urea compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3154970B1 (en) | 2019-11-06 |
| MX375282B (es) | 2025-03-06 |
| BR112016028345B1 (pt) | 2022-11-29 |
| US9808542B2 (en) | 2017-11-07 |
| AU2015274843B2 (en) | 2018-11-22 |
| WO2015191506A3 (en) | 2016-02-04 |
| US20170119912A1 (en) | 2017-05-04 |
| JP2017521387A (ja) | 2017-08-03 |
| EP3154970A4 (en) | 2017-11-15 |
| EP3154970A2 (en) | 2017-04-19 |
| WO2015188368A1 (en) | 2015-12-17 |
| ES2763095T3 (es) | 2020-05-27 |
| RU2016150404A (ru) | 2018-07-18 |
| DK3154970T3 (da) | 2020-01-20 |
| BR112016028345A8 (pt) | 2021-06-29 |
| RU2019115483A (ru) | 2019-06-13 |
| WO2015191506A2 (en) | 2015-12-17 |
| MX2016016384A (es) | 2017-05-01 |
| BR112016028345A2 (pt) | 2017-08-22 |
| RU2016150404A3 (enExample) | 2018-11-30 |
| CA2948528A1 (en) | 2015-12-17 |
| US20180071412A1 (en) | 2018-03-15 |
| JP6513107B2 (ja) | 2019-05-15 |
| KR102478430B1 (ko) | 2022-12-15 |
| HUE048395T2 (hu) | 2020-08-28 |
| RU2695373C2 (ru) | 2019-07-23 |
| CN106661018A (zh) | 2017-05-10 |
| AU2015274843A1 (en) | 2016-11-10 |
| US10022461B2 (en) | 2018-07-17 |
| KR20170016481A (ko) | 2017-02-13 |
| CA2948528C (en) | 2022-05-31 |
| PL3154970T3 (pl) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106661018B (zh) | 用作神经原纤维缠结显像剂的吡咯并[2,3-c]吡啶 | |
| JP6466335B2 (ja) | ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター | |
| CN110088099A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 | |
| CN102256493A (zh) | 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物 | |
| JP2016500073A (ja) | 寄生虫病の処置のための化合物および組成物 | |
| KR20230107800A (ko) | Hsd17b13 억제제 및 이의 용도 | |
| CN105358558A (zh) | 作为tau-pet-配体的二氮杂咔唑衍生物 | |
| KR102798858B1 (ko) | 추가로 치환된 트리아졸로 퀴녹살린 유도체 | |
| KR20180128937A (ko) | 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제 | |
| JP6392352B2 (ja) | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 | |
| CN112292183A (zh) | 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑 | |
| CN109988106A (zh) | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 | |
| TW201605858A (zh) | 縮合吡唑衍生物 | |
| TW202515544A (zh) | 作為ｃ－ｋｉｔ激酶抑制劑的醫藥化合物及組合物 | |
| WO2020135195A1 (zh) | 氨基吡啶类化合物及其制备方法和用途 | |
| TW202440574A (zh) | 作為ｐｋｍｙｔ１抑制劑的雜芳基化合物 | |
| TW201422610A (zh) | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 | |
| RU2788916C2 (ru) | Пирроло[2,3-с]пиридины в качестве визуализирующих агентов для нейрофибриллярных клубков | |
| CN104619694A (zh) | 适用作pde10抑制剂的氮杂环丁烷和哌啶化合物 | |
| TW202413367A (zh) | Ｔａｍ受體抑制劑 | |
| WO2024240231A1 (zh) | Fgfr2/3选择性抑制剂、药物组合物及其应用 | |
| TW202517629A (zh) | 蛋白質精胺酸酶甲基轉移酶-5抑制劑及其醫藥用途 | |
| WO2025007777A1 (zh) | 嘧啶类化合物、其制备方法及其医药用途 | |
| HK40046165B (zh) | 吡啶基及吡嗪基-(氮杂)吲哚磺酰胺 | |
| HK1164060A (en) | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221123 Address after: new jersey Patentee after: MERCK SHARP & DOHME B.V. Address before: new jersey Patentee before: MERCK SHARP & DOHME Corp. |
|
| TR01 | Transfer of patent right |